The Discovery of Polo-Like Kinase 4 Inhibitors: Design and Optimization of Spiro[cyclopropane-1,3′[3H]indol]-2′(1′H)-ones as Orally Bioavailable Antitumor Agents-Reference-Cited by-同舟云学术

The Discovery of Polo-Like Kinase 4 Inhibitors: Design and Optimization of Spiro[cyclopropane-1,3′[3H]indol]-2′(1′H)-ones as Orally Bioavailable Antitumor Agents

Published:2014-06-24 Issue:1 Volume:58 Page:130-146
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Sampson Peter B.¹,Liu Yong¹,Patel Narendra Kumar¹,Feher Miklos¹,Forrest Bryan¹,Li Sze-Wan¹,Edwards Louise¹,Laufer Radoslaw¹,Lang Yunhui¹,Ban Fuqiang¹,Awrey Donald E.¹,Mao Guodong¹,Plotnikova Olga¹,Leung Genie¹,Hodgson Richard¹,Mason Jacqueline¹,Wei Xin¹,Kiarash Reza¹,Green Erin¹,Qiu Wei²,Chirgadze Nickolay Y.²,Mak Tak W.¹,Pan Guohua¹,Pauls Henry W.¹

Affiliation:

1. Campbell Family Institute for Breast Cancer Research, TMDT East Tower, MaRS Centre, 101 College Street, Toronto, Ontario MG5 1L7, Canada

2. Princess Margaret Cancer Center, University Health Network, Toronto, Ontario M5G 2C4, Canada

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm500537u

Reference47 articles.

1. Targeted anti-mitotic therapies: can we improve on tubulin agents?

2. Mitotic drug targets and the development of novel anti-mitotic anticancer drugs